Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.
2.

Complete genome characterization of a rotavirus B (RVB) strain identified in Alpine goat kids with enteritis reveals inter-species transmission with RVB bovine strains.

Chen F, Knutson TP, Ciarlet M, Sturos M, Marthaler DG.

J Gen Virol. 2018 Apr;99(4):457-463. doi: 10.1099/jgv.0.001022. Epub 2018 Mar 8.

3.

Genome characterization of Turkey Rotavirus G strains from the United States identifies potential recombination events with human Rotavirus B strains.

Chen F, Knutson TP, Porter RE, Ciarlet M, Mor SK, Marthaler DG.

J Gen Virol. 2017 Dec;98(12):2931-2936. doi: 10.1099/jgv.0.000963. Epub 2017 Nov 23.

4.

Genotypic and epitope characteristics of group A porcine rotavirus strains circulating in Canada.

Naseer O, Jarvis MC, Ciarlet M, Marthaler DG.

Virology. 2017 Jul;507:53-63. doi: 10.1016/j.virol.2017.03.008. Epub 2017 Apr 8.

5.

Human P[6] Rotaviruses From Sub-Saharan Africa and Southeast Asia Are Closely Related to Those of Human P[4] and P[8] Rotaviruses Circulating Worldwide.

Heylen E, Zeller M, Ciarlet M, Lawrence J, Steele D, Van Ranst M, Matthijnssens J.

J Infect Dis. 2016 Oct 1;214(7):1039-49. doi: 10.1093/infdis/jiw247. Epub 2016 Jul 28.

PMID:
27471320
6.

Three-Level Mixed-Effects Logistic Regression Analysis Reveals Complex Epidemiology of Swine Rotaviruses in Diagnostic Samples from North America.

Homwong N, Diaz A, Rossow S, Ciarlet M, Marthaler D.

PLoS One. 2016 May 4;11(5):e0154734. doi: 10.1371/journal.pone.0154734. eCollection 2016.

7.

Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa.

Heylen E, Zeller M, Ciarlet M, Lawrence J, Steele D, Van Ranst M, Matthijnssens J.

Sci Rep. 2015 Oct 6;5:14658. doi: 10.1038/srep14658.

8.
9.

Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.

Lawrence J, He S, Martin J, Schödel F, Ciarlet M, Murray AV.

Hum Vaccin Immunother. 2014;10(8):2247-54. doi: 10.4161/hv.29107.

10.

Rapid detection and high occurrence of porcine rotavirus A, B, and C by RT-qPCR in diagnostic samples.

Marthaler D, Homwong N, Rossow K, Culhane M, Goyal S, Collins J, Matthijnssens J, Ciarlet M.

J Virol Methods. 2014 Dec;209:30-4. doi: 10.1016/j.jviromet.2014.08.018. Epub 2014 Sep 4.

PMID:
25194889
11.

VP6 genetic diversity, reassortment, intragenic recombination and classification of rotavirus B in American and Japanese pigs.

Marthaler D, Suzuki T, Rossow K, Culhane M, Collins J, Goyal S, Tsunemitsu H, Ciarlet M, Matthijnssens J.

Vet Microbiol. 2014 Aug 27;172(3-4):359-66. doi: 10.1016/j.vetmic.2014.05.015. Epub 2014 Jun 2.

12.

Widespread rotavirus H in commercially raised pigs, United States.

Marthaler D, Rossow K, Culhane M, Goyal S, Collins J, Matthijnssens J, Nelson M, Ciarlet M.

Emerg Infect Dis. 2014 Jul;20(7):1195-8. doi: 10.3201/eid2007.140034.

13.

Identification, phylogenetic analysis and classification of porcine group C rotavirus VP7 sequences from the United States and Canada.

Marthaler D, Rossow K, Culhane M, Collins J, Goyal S, Ciarlet M, Matthijnssens J.

Virology. 2013 Nov;446(1-2):189-98. doi: 10.1016/j.virol.2013.08.001. Epub 2013 Aug 29.

14.

Global distribution of group A rotavirus strains in horses: a systematic review.

Papp H, Matthijnssens J, Martella V, Ciarlet M, Bányai K.

Vaccine. 2013 Nov 19;31(48):5627-33. doi: 10.1016/j.vaccine.2013.08.045. Epub 2013 Aug 28. Review.

PMID:
23994380
15.

The path to an RSV vaccine.

Shaw CA, Ciarlet M, Cooper BW, Dionigi L, Keith P, O'Brien KB, Rafie-Kolpin M, Dormitzer PR.

Curr Opin Virol. 2013 Jun;3(3):332-42. doi: 10.1016/j.coviro.2013.05.003. Epub 2013 May 30. Review.

PMID:
23727193
16.

Review of group A rotavirus strains reported in swine and cattle.

Papp H, László B, Jakab F, Ganesh B, De Grazia S, Matthijnssens J, Ciarlet M, Martella V, Bányai K.

Vet Microbiol. 2013 Aug 30;165(3-4):190-9. doi: 10.1016/j.vetmic.2013.03.020. Epub 2013 Apr 4. Review.

PMID:
23642647
17.

Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?

Matthijnssens J, Nakagomi O, Kirkwood CD, Ciarlet M, Desselberger U, Van Ranst M.

Expert Rev Vaccines. 2012 Nov;11(11):1347-54. doi: 10.1586/erv.12.105. Review.

PMID:
23249234
18.

Complete genetic characterization of human G2P[6] and G3P[6] rotavirus strains.

Heylen E, Zeller M, Ciarlet M, De Coster S, Van Ranst M, Matthijnssens J.

Infect Genet Evol. 2013 Jan;13:27-35. doi: 10.1016/j.meegid.2012.08.019. Epub 2012 Sep 12.

PMID:
22982160
19.

Detection of substantial porcine group B rotavirus genetic diversity in the United States, resulting in a modified classification proposal for G genotypes.

Marthaler D, Rossow K, Gramer M, Collins J, Goyal S, Tsunemitsu H, Kuga K, Suzuki T, Ciarlet M, Matthijnssens J.

Virology. 2012 Nov 10;433(1):85-96. doi: 10.1016/j.virol.2012.07.006. Epub 2012 Aug 9.

20.

The epidemiology of respiratory syncytial virus lower respiratory tract infection on young children.

Cooper BW, Dormitzer PR, Ciarlet M.

Pediatr Infect Dis J. 2012 Aug;31(8):883; author reply 883-4. doi: 10.1097/INF.0b013e31825c11b6. No abstract available.

PMID:
22801098
21.

Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.

Zaman K, Yunus M, El Arifeen S, Azim T, Faruque AS, Huq E, Hossain I, Luby SP, Victor JC, Dallas MJ, Lewis KD, Rivers SB, Steele AD, Neuzil KM, Ciarlet M, Sack DA.

Vaccine. 2012 Apr 27;30 Suppl 1:A94-100. doi: 10.1016/j.vaccine.2011.07.117.

PMID:
22520143
22.

Immunogenicity of the pentavalent rotavirus vaccine in African infants.

Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A86-93. doi: 10.1016/j.vaccine.2011.10.006.

PMID:
22520142
23.

Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.

Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A79-85. doi: 10.1016/j.vaccine.2012.01.022.

PMID:
22520141
24.

Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, Neuzil KM, Kotloff KL, Levine MM.

Vaccine. 2012 Apr 27;30 Suppl 1:A71-8. doi: 10.1016/j.vaccine.2011.11.094.

PMID:
22520140
25.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
26.

Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.

Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A52-60. doi: 10.1016/j.vaccine.2011.08.043.

PMID:
22520137
27.

Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.

Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM.

Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124.

PMID:
22520132
28.

Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia.

Lewis KD, Dallas MJ, Victor JC, Ciarlet M, Mast TC, Ji M, Armah G, Zaman K, Ferraro A, Neuzil KM.

Vaccine. 2012 Apr 27;30 Suppl 1:A159-66. doi: 10.1016/j.vaccine.2011.07.126.

PMID:
22520126
29.

Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.

Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM, Ciarlet M.

Vaccine. 2012 Apr 27;30 Suppl 1:A106-13. doi: 10.1016/j.vaccine.2011.11.091.

PMID:
22520119
30.

VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation.

Matthijnssens J, Otto PH, Ciarlet M, Desselberger U, Van Ranst M, Johne R.

Arch Virol. 2012 Jun;157(6):1177-82. doi: 10.1007/s00705-012-1273-3. Epub 2012 Mar 20.

PMID:
22430951
31.

Complete molecular genome analyses of equine rotavirus A strains from different continents reveal several novel genotypes and a largely conserved genotype constellation.

Matthijnssens J, Miño S, Papp H, Potgieter C, Novo L, Heylen E, Zeller M, Garaicoechea L, Badaracco A, Lengyel G, Kisfali P, Cullinane A, Collins PJ, Ciarlet M, O'Shea H, Parreño V, Bányai K, Barrandeguy M, Van Ranst M.

J Gen Virol. 2012 Apr;93(Pt 4):866-75. doi: 10.1099/vir.0.039255-0. Epub 2011 Dec 21.

PMID:
22190012
32.

Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq.

Zeller M, Patton JT, Heylen E, De Coster S, Ciarlet M, Van Ranst M, Matthijnssens J.

J Clin Microbiol. 2012 Mar;50(3):966-76. doi: 10.1128/JCM.05590-11. Epub 2011 Dec 21.

33.

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil.

El Khoury AC, Mast TC, Ciarlet M, Markson L, Goveia MG, Munford V, Rácz ML.

Mem Inst Oswaldo Cruz. 2011 Aug;106(5):541-5.

34.

Molecular characterization of genotype G6 human rotavirus strains detected in Italy from 1986 to 2009.

De Grazia S, Martella V, Rotolo V, Bonura F, Matthijnssens J, Bányai K, Ciarlet M, Giammanco GM.

Infect Genet Evol. 2011 Aug;11(6):1449-55. doi: 10.1016/j.meegid.2011.05.015. Epub 2011 May 26.

PMID:
21640847
35.

Multiple reassortment and interspecies transmission events contribute to the diversity of feline, canine and feline/canine-like human group A rotavirus strains.

Matthijnssens J, De Grazia S, Piessens J, Heylen E, Zeller M, Giammanco GM, Bányai K, Buonavoglia C, Ciarlet M, Martella V, Van Ranst M.

Infect Genet Evol. 2011 Aug;11(6):1396-406. doi: 10.1016/j.meegid.2011.05.007. Epub 2011 May 13.

PMID:
21609783
36.

Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG).

Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Bányai K, Brister JR, Buesa J, Esona MD, Estes MK, Gentsch JR, Iturriza-Gómara M, Johne R, Kirkwood CD, Martella V, Mertens PP, Nakagomi O, Parreño V, Rahman M, Ruggeri FM, Saif LJ, Santos N, Steyer A, Taniguchi K, Patton JT, Desselberger U, Van Ranst M.

Arch Virol. 2011 Aug;156(8):1397-413. doi: 10.1007/s00705-011-1006-z. Epub 2011 May 20.

37.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
38.

Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine.

Goveia MG, Ciarlet M, Owen KE, Ranucci CS.

Ann N Y Acad Sci. 2011 Mar;1222:14-8. doi: 10.1111/j.1749-6632.2011.05970.x. Review.

PMID:
21434938
39.

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries.

El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG.

Hum Vaccin. 2011 May;7(5):506-10. Epub 2011 May 1.

40.

A feline rotavirus G3P[9] carries traces of multiple reassortment events and resembles rare human G3P[9] rotaviruses.

Martella V, Potgieter AC, Lorusso E, De Grazia S, Giammanco GM, Matthijnssens J, Bányai K, Ciarlet M, Lavazza A, Decaro N, Buonavoglia C.

J Gen Virol. 2011 May;92(Pt 5):1214-21. doi: 10.1099/vir.0.027425-0. Epub 2011 Jan 12.

PMID:
21228122
41.

Molecular characterization of equine rotaviruses circulating in Argentinean foals during a 17-year surveillance period (1992-2008).

Garaicoechea L, Miño S, Ciarlet M, Fernández F, Barrandeguy M, Parreño V.

Vet Microbiol. 2011 Mar 24;148(2-4):150-60. doi: 10.1016/j.vetmic.2010.08.032. Epub 2010 Sep 8.

PMID:
20943330
42.

RotaTeq: Progress toward developing world access.

Goveia MG, Nelson CB, Ciarlet M.

J Infect Dis. 2010 Sep 1;202 Suppl:S87-92. doi: 10.1086/653546.

PMID:
20684723
43.

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M.

Lancet. 2010 Aug 21;376(9741):615-23. doi: 10.1016/S0140-6736(10)60755-6. Epub 2010 Aug 6.

PMID:
20692031
44.

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM.

Lancet. 2010 Aug 21;376(9741):606-14. doi: 10.1016/S0140-6736(10)60889-6. Epub 2010 Aug 6.

PMID:
20692030
45.

Separation of rotavirus double-layered particles and triple-layered particles by capillary zone electrophoresis.

Mathis PK, Ciarlet M, Campbell KM, Wang S, Owen KE, Ranheim TS.

J Virol Methods. 2010 Oct;169(1):13-21. doi: 10.1016/j.jviromet.2010.06.006. Epub 2010 Jun 25.

PMID:
20599561
46.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M.

Eur J Pediatr. 2010 Nov;169(11):1379-86. doi: 10.1007/s00431-010-1242-3. Epub 2010 Jun 18.

47.

Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq.

Matthijnssens J, Joelsson DB, Warakomski DJ, Zhou T, Mathis PK, van Maanen MH, Ranheim TS, Ciarlet M.

Virology. 2010 Aug 1;403(2):111-27. doi: 10.1016/j.virol.2010.04.004. Epub 2010 May 6.

48.

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.

Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M.

Pediatr Infect Dis J. 2010 Oct;29(10):957-63. doi: 10.1097/INF.0b013e3181e28e6e.

PMID:
20442684
49.

Reassortment of human rotavirus gene segments into G11 rotavirus strains.

Matthijnssens J, Rahman M, Ciarlet M, Zeller M, Heylen E, Nakagomi T, Uchida R, Hassan Z, Azim T, Nakagomi O, Van Ranst M.

Emerg Infect Dis. 2010 Apr;16(4):625-30. doi: 10.3201/eid1604.091591.

50.

Rotavirus enterotoxin NSP4 has mucosal adjuvant properties.

Kavanagh OV, Ajami NJ, Cheng E, Ciarlet M, Guerrero RA, Zeng CQ, Crawford SE, Estes MK.

Vaccine. 2010 Apr 19;28(18):3106-11. doi: 10.1016/j.vaccine.2010.02.063. Epub 2010 Mar 1.

Supplemental Content

Loading ...
Support Center